Home » Topics » Regulatory » EMA

EMA
RSS

EMA grants orphan drug designation to avacopan for C3 glomerulopathy

May 24, 2017

EMA committee recommends approval of Oxervate for neurotrophic keratitis

May 23, 2017

EMA committee gives positive opinion to brodalumab for plaque psoriasis

May 23, 2017

Cariprazine granted positive opinion in Europe for the treatment of schizophrenia

May 23, 2017

Cardioxane receives positive CHMP opinion in Europe

May 22, 2017

Articular cartilage product granted positive opinion from CHMP for European approval

May 22, 2017

Chiesi's triple combination for the treatment of COPD receives positive opinion from EMA

May 22, 2017

EMA accepts for review MAA for adalimumab biosimilar, FKB-327

May 22, 2017

EMA committee backs approval of Zykadia for first-line use in ALK+ NSCLC

May 22, 2017

EMA validates application seeking expanded approval of Sprycel

May 22, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...